ClearPoint Neuro (CLPT) Stock Price, News & Analysis

Company Overview

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Key Stats

• Today's Range: $16.67 to $17.45
• 50-Day Range: $14.63 to $18.90
• 52-Week Range: $5.11 to $19.22
• Volume: 191,341 shs
• Average Volume: 201,089 shs
• Market Capitalization: $461.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.67
• Consensus Rating: Buy

ClearPoint Neuro Stock Analysis - MarketRank™

ClearPoint Neuro scored higher than 38% of companies evaluated by MarketBeat, and ranked 716th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

ClearPoint Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ClearPoint Neuro has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.66) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ClearPoint Neuro is -24.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ClearPoint Neuro is -24.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ClearPoint Neuro has a P/B Ratio of 19.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.37% of the outstanding shares of ClearPoint Neuro have been sold short.

Short Interest Ratio / Days to Cover

ClearPoint Neuro has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ClearPoint Neuro has recently decreased by 22.08%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ClearPoint Neuro does not currently pay a dividend.

Dividend Growth

ClearPoint Neuro does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.37% of the outstanding shares of ClearPoint Neuro have been sold short.

Short Interest Ratio / Days to Cover

ClearPoint Neuro has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ClearPoint Neuro has recently decreased by 22.08%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.18

News Sentiment

ClearPoint Neuro has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for ClearPoint Neuro this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for CLPT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

1 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ClearPoint Neuro insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.11% of the stock of ClearPoint Neuro is held by insiders.

Percentage Held by Institutions

Only 30.08% of the stock of ClearPoint Neuro is held by institutions.

CLPT Stock Analysis - Frequently Asked Questions

How have CLPT shares performed this year?

ClearPoint Neuro's stock was trading at $15.38 at the beginning of 2025. Since then, CLPT shares have increased by 8.7% and is now trading at $16.72.
View the best growth stocks for 2025 here.

How were ClearPoint Neuro's earnings last quarter?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) posted its earnings results on Thursday, November, 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The business earned $8.12 million during the quarter, compared to analysts' expectations of $8.07 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 62.10% and a negative net margin of 59.64%.

Who are ClearPoint Neuro's major shareholders?

Top institutional shareholders of ClearPoint Neuro include Vanguard Group Inc. (4.53%), Essex Investment Management Co. LLC (1.48%), CM Management LLC (1.05%) and Millennium Management LLC (1.05%).
View institutional ownership trends.

How do I buy shares of ClearPoint Neuro?

Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ClearPoint Neuro own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ClearPoint Neuro investors own include Arista Networks (ANET), NVIDIA (NVDA), CrowdStrike (CRWD), Axon Enterprise (AXON), Advanced Micro Devices (AMD), Cadence Design Systems (CDNS) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CLPT
• CUSIP: N/A
• CIK: 1285550
• Web: www.clearpointneuro.com
• Phone: (949) 900-6833
• Fax: 949-900-6834
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $19.67
• High Stock Price Target: $30.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +17.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,090,000.00
• Net Margins: -59.64%
• Pretax Margin: -59.64%
• Return on Equity: -62.10%
• Return on Assets: -38.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.54
• Quick Ratio: 3.61

Sales & Book Value

• Annual Sales: $23.95 million
• Price / Sales: 19.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.86 per share
• Price / Book: 19.52

Miscellaneous

• Outstanding Shares: 27,580,000
• Free Float: 25,900,000
• Market Cap: $463.07 million
• Optionable: Optionable
• Beta: 1.03